$3.46
2.81% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Prime Medicine Stock price

$3.46
-0.85 19.72% 1M
-3.30 48.82% 6M
-5.40 60.95% YTD
-6.08 63.73% 1Y
-13.54 79.65% 3Y
-13.54 79.65% 5Y
-13.54 79.65% 10Y
NYSE, Closing price Fri, Sep 27 2024
-0.10 2.81%
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Key metrics

Market capitalization $427.31m
Enterprise Value $306.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 518.68
P/S ratio (TTM) P/S ratio 724.25
P/B ratio (TTM) P/B ratio 2.17
Revenue (TTM) Revenue $590.00k
EBIT (operating result TTM) EBIT $-210.02m
Free Cash Flow (TTM) Free Cash Flow $-205.20m
Cash position $162.87m
EPS (TTM) EPS $-2.13
P/E forward negative
P/S forward 91.97
EV/Sales forward 65.86
Short interest 28.47%
Show more

Is Prime Medicine a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Prime Medicine Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Prime Medicine forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Prime Medicine forecast:

Buy
83%
Hold
17%

Financial data from Prime Medicine

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.59 0.59
-
100%
- Direct Costs 8.47 8.47
45% 45%
1,436%
-7.88 -7.88
49% 49%
-1,336%
- Selling and Administrative Expenses 30 30
513% 513%
5,151%
- Research and Development Expense 163 163
37% 37%
27,673%
-202 -202
44% 44%
-34,159%
- Depreciation and Amortization 8.47 8.47
45% 45%
1,436%
EBIT (Operating Income) EBIT -210 -210
35% 35%
-35,596%
Net Profit -217 -217
45% 45%
-36,854%

In millions USD.

Don't miss a Thing! We will send you all news about Prime Medicine directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prime Medicine Stock News

Positive
The Motley Fool
about one month ago
Prime Medicine is pioneering prime-editing technology for genetic disorders, with the potential for long-term growth despite its early-stage status. Rocket Lab USA is capturing market share in the expanding commercial space industry with its small satellite launch services and vertical-integration strategy.
Positive
InvestorPlace
4 months ago
Biotech stocks are not for the faint of heart. It is a sector that can provide life-changing gains or cause an investment to head towards zero.
Positive
The Motley Fool
4 months ago
Alphabet manages more than $7 billion in equity investments, including a publicly traded portfolio. Its biggest holding competes with Microsoft's Github.
More Prime Medicine News

Company Profile

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Head office United States
CEO Keith Gottesdiener
Employees 234
Founded 2019
Website www.primemedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today